Altace Will Gain 1,000 Wyeth Reps Through Copromotion Deal
Executive Summary
Wyeth-Ayerst is allocating approximately 1,000 sales reps to promote King's Altace in the U.S. and Puerto Rico, under a copromotion agreement announced June 23.
You may also be interested in...
Mylan Places Big Bet On Antihypertensives: $4 Bil. Deal For King
Mylan's proposed acquisition of King is a big move by the generic company to carve out a leading position in the branded antihypertensive market
Mylan Places Big Bet On Antihypertensives: $4 Bil. Deal For King
Mylan's proposed acquisition of King is a big move by the generic company to carve out a leading position in the branded antihypertensive market
King Altace Label Highlights Data Supporting Efficacy In Diabetic Patients
Labeling for King Pharmaceutical's ACE inhibitor Altace has been updated to highlight substudy data supporting efficacy in diabetic patients, following FDA approval Oct. 5 for reduction in risk of myocardial infarction, stroke and death from cardiovascular causes.